Cizzle Biotechnology Holdings Update and Extension on Put Option with Conduit

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat inflammatory pulmonary and cardiovascular disease to Conduit Pharmaceuticals for a total consideration of £3.25 million, to be satisfied through the issuance of new shares in Conduit and its prospective parent Murphy Canyon Acquisition Corp. (NASDAQ: MURF).

Cizzle announced on 15 August 2023 that Murphy had formally notified its current shareholders that a special meeting was to be held on 7 September 2023 for Murphy shareholders to provide their approval for the transaction.  The Board of Cizzle have now been informed that this meeting has been postponed and will now be held at 10:00 a.m., Eastern Time, on Wednesday 20 September 2023. As a consequence, the Option has been extended until 25 October 2023.

Should Cizzle exercise the Option and the Conduit-Murphy Transaction complete, the Company will hold shares in the Conduit-Murphy merged business, thereafter to be called Conduit, which will become a publicly traded company on NASDAQ in the USA. Once issued, the new shares in Conduit to be provided to Cizzle pursuant to the exercise of the Option will not be subject to any restrictions.

Cizzle Biotechnology Holdings plc is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
    Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally.
    Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA.
    Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay.
    Cizzle Biotechnology expands its CIZ1B biomarker test agreement to the Caribbean, accelerating market entry for early lung cancer detection in 2025.
    Discover how Cizzle Biotechnology's innovative CIZ1B biomarker is revolutionizing early lung cancer detection and leveraging strategic partnerships.
    Cizzle Biotechnology's Dr Allan Syms discusses a pivotal licensing deal for the CIZ1B biomarker, enhancing early lung cancer detection strategies.

      Search

      Search